

## ***RELAY Thoracic Stent-Graft shows safety and efficacy in the endovascular treatment of a broad “real life” range of Thoracic Aortic Diseases***

**Barcelona, Spain, December 1, 2010** – The final results of the international RESTORE (Relay™ Endovascular Registry for Thoracic Disease) registry have been published<sup>1</sup> in the Journal of Vascular Surgery. The paper confirms the safety and efficacy of the RELAY Thoracic Stent Graft in the treatment of a broad range of thoracic aortic pathologies.

### **Landmark study**

The RESTORE study is a multicenter, European, prospective and monitored clinical registry that included 304 patients with any of the following thoracic aortic pathologies: Aneurysms, Dissections, Pseudoaneurysms, Penetrating Atherosclerotic Ulcers (PAUs), Intramural Hematomas, and Trauma or Emergent applications. The study included patients in twenty centres in Spain, Germany, Italy, Austria, France, Greece and The Netherlands

Patients were followed at 1, 6, 12 and 24-month intervals. The whole series obtained an average follow-up time of 334 days.

### **Key clinical outcomes from the RESTORE registry**

According to the RESTORE study, RELAY Thoracic Stent-Graft demonstrated:

- A extremely low stroke rate (1,6%) within the whole population, despite the proximal landing zone was in the aortic arch in 79% of cases, enrollment of high risk patients, acute situations and difficult anatomies
- A low endoleak rate (4,6%) of any type
- No intra-operative conversion to open procedures
- In 80% of cases, only 1 stent-graft was required for complete treatment, thus minimizing risk of disconnection, time of intervention, fluoroscopic load and cost.
- 30-Day mortality (7,2%) and survival rate at 12 months (97,3%) and 24 months (95,9%)

“The results of RESTORE support the safety of thoracic endovascular aortic repair with the RELAY stent-graft, even in acute and complicated situations. The device was highly efficient in angulated aortic anatomies, with acceptable mortality and a low rate of neurologic complications” said Vicent Riambau, MD, the principal investigator of the study, Chief of the Vascular Surgery Division of Thorax Institute and Coordinator of the Endovascular Surgery Program at Hospital Clinic, University of Barcelona, Spain.

### **ABOUT BOLTON MEDICAL**

Bolton Medical is part of Werfen Group, an international group producing and selling products in the healthcare industry. Bolton Medical's focus is innovative thoracic endovascular therapies with a new generation of thoracic stent-graft called RELAY. RELAY was specifically designed for the thoracic aorta with key benefits in precise placement of the stent and flexibility through the Spiral Support Strut. For more information visit <http://www.boltonmedical.com>

### **MEDIA CONTACT**

USA: Candace DeLeonardis +1.954.636.9785 [cdeleonardis@boltonmedical.com](mailto:cdeleonardis@boltonmedical.com)  
International: Carlos Camps +34.938.176.310 [carlos.camps@boltonmedical.com](mailto:carlos.camps@boltonmedical.com)

1. Riambau et al. Final operative and midterm results of the European experience in the RELAY Endovascular Registry for Thoracic Disease (RESTORE) study. JOURNAL OF VASCULAR SURGERY. doi:10.1016/j.jvs.2010.09.05